Ebert, Karolin <br/><br/>
MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.  [electronic resource] 

 -  PloS one  2019 
 - e0223225 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0223225  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Afatinib--pharmacology<br/>Cell Line, Tumor<br/>Cell Movement--genetics<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--antagonists & inhibitors<br/>Gene Knockdown Techniques<br/>Humans<br/>Intravital Microscopy<br/>Microscopy, Fluorescence<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-met--genetics<br/>RNA, Small Interfering--metabolism<br/>Stomach Neoplasms--drug therapy<br/>Time-Lapse Imaging